Table 4. Characteristics of *S*. Enteritidis carrying *qnrS1..*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ID | MIC (mg/L) | Resistance to other than quinolones\* |  MLVA types | **Source of isolate** | *gyrA* |
| NAL | CIP | NOR | Year | Specimen | Regions\*\* |
| 50 | 16 | 0.25 | 1 | AMP/STR | 5-5-11-7-3 | 2005 | stool | BK | WT |
| 92 | 16 | 0.38 | 1.5 | AMP/STR | 5-5-11-7-3 | 2005 | blood | NE | WT |
| 106 | 16 | 0.38 | 2.0 | AMP/STR | 5-5-11-7-3 | 2006 | stool | N | WT |
| 138 | 16 | 0.38 | 1.5 | AMP/STR | 5-5-9-7-3 | 2006 | blood | C | WT |
| 142 | 16 | 0.38 | 1.5 | AMP/STR | 5-5-11-7-3 | 2006 | blood | NE | WT |
| 77 | 24 | 0.38 | 1 | AMC/AMP/STR | 5-5-11-7-3 | 2005 | blood | BK | WT |
| 102 | 24 | 0.38 | 2 | AMP/STR | 5-5-11-7-3 | 2006 | stool | N | WT |
| 110 | 24 | 0.38 | 1.5 | AMP | 5-5-12-7-3 | 2006 | stool | S | WT |
| 114 | 24 | 0.38 | 1.5 | AMP/STR | 5-5-11-7-3 | 2006 | stool | BK | WT |
| 116 | 24 | 0.38 | 1.5 | AMP/STR | 5-5-11-7-3 | 2006 | stool | BK | WT |
| 123 | 24 | 0.38 | 1.5 | AMP/STR | 5-5-11-7-3 | 2006 | stool | N | WT |
| 128 | 24 | 0.38 | 1.5 | AMC/TET/AMP/STR | 5-5-11-7-3 | 2006 | blood | NE | WT |
| 156 | 24 | 0.38 | 1.5 | AMP/STR | 5-5-11-7-3 | 2007 | stool | W | WT |
| 160 | 24 | 0.38 | 1.5 | AMP/STR | 5-5-10-7-3 | 2007 | stool | C | WT |
| 177 | 24 | 0.38 | 1.5 | AMP/STR | 5-5-11-7-3 | 2007 | blood | C | WT |
| 117 | 32 | 0.38 | 2 | AMP/STR | 5-5-12-7-3 | 2006 | stool | W | WT |
| 131 | 32 | 0.38 | 1.5 | AMP/STR | 5-5-11-7-3 | 2006 | blood | N | WT |
| 134 | 32 | 0.5 | 2 | AMP/TET | 5-5-11-7-3 | 2006 | blood | NE | WT |
| 135 | ≥256 |  2 | 3 | TET | 5-5-10-7-3 | 2006 | blood | S | Ser83Tyr |

MIC, minimum inhibitory concentrations. MLVA, multiple-locus variable number tandem repeat analysis. \*AMC, amoxicillin+clavulanic acid; AMP, ampicillin; STR, streptomycin; TET, tetracycline. \*\*BK, Bangkok; C, Central provinces; E, Eastern provinces; N, Northern provinces; NE, Northeastern provinces; S, Southern provinces; W, Western provinces.